Immuneel Therapeutics Pvt. Ltd.

A Proud Moment at Bengaluru Tech Summit 2024 as Dr. Kiran Mazumdar Shaw graced the inaugural ceremony alongside the Chief Minister of Karnataka and other distinguished luminaries! We are delighted to share that Dr. Lakshmikanth Gandikota, our Head of Research and Development, MSAT, Intellectual Property, and Translational Research, had the incredible opportunity to participate in the panel discussion on "Next-Gen Immunotherapies for Cancer" at the prestigious Bengaluru Tech Summit 2024. It was an honour to share the stage with some of the most visionary minds in the field: Dr. Jyothsna Rao, Research Director, International Stem Cell Services Dr. Kavitha Iyer Rodrigues, CEO, Zumutor Biologics Dr. Ujjwal Rao, CEO, Rector Healthcare Keynote Speaker: Dr. Claire Mazumdar, CEO, Bicara Therapeutics Moderator: Dr. Vishal Rao, Director, HCG Cancer Centre The session highlighted cutting-edge advancements in immunotherapy, collaborative innovation, and the shared commitment to revolutionizing cancer treatment. Our Head of R&D brought unique insights into CAR T-cell therapy development, sparking meaningful dialogue with fellow experts and attendees. We thank the organizers and our esteemed co-panelists for this enriching experience. Let’s continue pushing the boundaries of what’s possible in the fight against cancer! Lakshmikanth Gandikota Amit Mookim #BengaluruTechSummit2024 #InnovationInCancerCare #Immunotherapy #CellAndGeneTherapy 

At Haematocon 2024, held in Nagpur from November 7th to 10th, we witnessed engaging discussions and scientific advancements in haemato-oncology. One of the highlights was Dr. Sharat Damodar, Chairman of Oncology at Narayana Health Bangalore, presenting 18-month clinical trial data on Qartemi, our CD-19 CAR T cell therapy approved for relapsed/refractory non-Hodgkin lymphoma. This critical data underscores the therapy's potential to provide new hope for patients battling aggressive blood cancers in India. Immuneel's commercial team was actively engaged throughout the conference, connecting with esteemed key opinion leaders (KOLs) from across the country. The scientific discussions and insights shared reinforced the importance of collaboration and innovation as we continue to pioneer accessible, high-quality CAR T therapies in India. We are grateful to Haematocon 2024 for providing an excellent platform to exchange knowledge and engage with the brightest minds in hematology. Immuneel remains committed to advancing our mission of enabling affordable, cutting-edge cell and gene therapies for Indian patients. #cellandgenetherapy #cancertreatment #Haematocon2024

Cutting edge technologies. Traditional values. Puja@Immuneel. At Immuneel, we believe in the power of tradition to bring people together and celebrate the values that drive us forward. This year, we marked the joyous occasion of Dussehra with great enthusiasm and the Ayudha Pooja at our facility was a moment of reflection and gratitude, as we sought blessings and divine guidance. This ceremony symbolizes our respect for the place of work that supports our mission in every step of our journey. Wishing everyone a prosperous and joyful Dussehra! Amit Mookim Lakshmikanth Gandikota Giri C Nitha Paul Rebu Ninan Akhil Agarwal Juthika C Anupam Chhabra, MD, MBA Yogananth Rajendran M.Pharm.RAC #DussehraCelebration #AyudhaPooja #TeamSpirit #WorkplaceCulture #ManufacturingExcellence #FestiveVibes #Gratitude #TogetherWeGrow

Reflecting on the Essence of the EHA Conference in Mumbai! Last week, the Immuneel team—Ms. Juthika C, Mr. Akhil Agarwal, Dr. Anupam Chhabra, MD, MBA, Mr. Rebu Ninan, and our CEO, Amit Mookim had the privilege of attending the prestigious Essence of EHA conference. A major highlight was the insightful presentation by Dr. sharat damodar, who shared our long-term clinical data on Qartemi (varnimcabtagene autoleucel), India's first commercially approved global CAR T cell therapy. Qartemi, approved for treating adult non-Hodgkin lymphoma (NHL), was in the spotlight as we revealed exciting new clinical data. The response was overwhelming, and we’re proud to see how this breakthrough therapy is gaining attention for its potential to address the unmet needs of patients with relapsed refractory B-NHL. It was a great opportunity to connect with experts from across the country and discuss the future of cancer care, especially in the realm of CAR T therapies. Thank you to everyone who contributed to making this event a success. We’re more motivated than ever to keep pushing the boundaries in cell and gene therapy! #EssenceofEHA #Qartemi #CARTTherapy #CellAndGeneTherapy #HealthcareInnovation #CancerResearch #Immuneel #ClinicalData

We’re #hiring.

Immuneel Therapeutics Welcomes Amit Mookim as CEO   We are excited to announce the appointment of Mr. Amit Mookim as the new Chief Executive Officer of Immuneel Therapeutics. Amit brings over 20 years of experience spanning life sciences, technology, and private equity, and we are confident that his vision and leadership will help drive our next phase of growth and impact in the cell and gene therapy space.   Amit joins us from IQVIA, where he successfully led South Asia as Managing Director, overseeing operations across 20,000+ professionals and significantly expanding the commercial business. Prior to IQVIA, Amit headed healthcare at KPMG India, where he built the practice from the ground up, working with hospitals, PE funds, and global healthcare companies to establish their presence in India. His contributions as an advisor to national bodies and industry organizations have made him a respected thought leader in healthcare strategy and market access. In the field of life sciences, he chipped in to guide the National Health Authority on creating market access for start-ups in PMJAY and has advised industry organizations such as the Indian Pharmaceutical Alliance, APACMED, OPPI, FICCI, and NATHEALTH on universal healthcare, market access, pricing, and innovation. Additionally, he has been involved in leadership committees and task forces to drive collaborative programs between industry and regulators. He possesses deep knowledge of commercializing new business models and expanding organizations and has worked across South Asia, APAC, the Middle East, Sub-Saharan Africa, and Europe.   Our co-founders, Dr. Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee, and Dr. Kush Parmar have expressed their confidence that under Amit's leadership, Immuneel will continue to break new ground in cancer immunotherapy. As we move forward, Amit will focus on accelerating access to our CAR-T therapies, building global partnerships, and expanding our footprint across India and beyond.   Please join us in welcoming Amit to the Immuneel team as we continue our mission to transform cancer care for patients in India and beyond. Amit Mookim   #Leadership #Innovation #CellTherapy #GeneTherapy #Immunotherapy #CancerTreatment #Immuneel #CEO

Proud Moment for Immuneel Therapeutics! We are excited to announce that Immuneel Therapeutics has been honoured with the prestigious “BIRAC Innovator Award 2024” in recognition of the significant contribution made by the team towards the high level of innovation research towards “Development of CD19 CAR-T Cell Therapy (Qartemi – varnimcabtagene autoleucel/ IMN-003A) for relapsed/refractory-cell non-Hodgkin’s lymphoma”  from the Biotechnology Industry Research Assistance Council (BIRAC), a Public Sector Undertaking under the Department of Biotechnology (DBT), for our groundbreaking work in advancing cell and gene therapies in India.   This recognition was presented on 14th September 2024 at the Global Bio-India 2024 event in Delhi, marking an important milestone for Immuneel and our commitment to transforming cancer treatment with cutting-edge innovation. We are particularly proud of Qartemi (varnimcabtagene autoleucel), our novel CAR T cell therapy, which is paving the way for more effective, personalized cancer care, for adult patients with relapsed/ refractory B-cell non-Hodgkin’s lymphoma.   Mr. Amit Mookim, CEO, of Immuneel Therapeutics accepted the award on behalf of our team, who have collectively been instrumental in driving forward our mission to make Qartemi and other advanced therapies more accessible and affordable for patients in India and beyond.   This award is a testament to the collective efforts of the entire Immuneel team and our partners. Together, we are redefining the future of cancer care.   Amit Mookim Kiran Mazumdar Shaw Lakshmikanth Gandikota Dr. Md. Manzoor Akheel Anupam Chhabra, MD, MBA #Immuneel #BIRAC #Qartemi #CARTcellTherapy #GlobalBioIndia #CancerCare #Biotechnology #CellAndGeneTherapy #HealthcareInnovation    

We're #hiring a new Regional Cell Therapy Accounts Specialists in New Delhi, Delhi. Apply today or share this post with your network.

Arun Anand, MD Board Director & COO Immuneel Therapeutics Pvt. Ltd. was invited to speak at the inaugural edition of the Bengaluru Pharma Summit (2024) on 21st June, Bengaluru organized by Express Pharma, a respected industry publication from The Indian Express Group. The session featured pharma leaders discussing and touching upon important aspects like need to focus and invest on building and training talent to drive progress in the pharma industry, skilled R&D talent, and cost-effective manufacturing as India Pharma’s competitive advantage & India’s pharma shift to becoming the 'Discovery Pharmacy of the World'. At the panel “Bengaluru: Powering innovation in India Pharma Inc”, Dr Anand and other panelists highlighted the conducive environment, stellar academic centers, risk appetite and resident talent within the city making it an innovation powerhouse for pharma and biopharma, and the new areas of cell and gene therapy. Dr Anand elaborated on Bengaluru’s unique ecosystem that enabled Immuneel flourish as a start-up in the cell & gene therapy space, as well as the challenges that need to be mitigated for many more healthcare start-ups to bring pharma/biotech innovation forward. Immuneel started its pioneering journey with establishment in Bengaluru in 2019, building an innovation culture driven by inspirational leadership, out-of-the-box thinking and a collaborative mindset leading to its first product -Varnimcabtagene autoleucel (CD19 CAR-T) - being approved and ready for commercial access. Under the theme, ‘Co-creating an ecosystem for pharma innovation’, the Bengaluru Pharma Summit brought together experts, thought leaders, and veterans from the industry and regulatory bodies providing an overview and assessment of the potential areas for influencing business performance with value generation and sustainability. To know more about us, visit: www.immuneel.com #BengaluruPharmaSummit2024 #paneldiscussion #leadershipsession #immuneel #expresspharma #gratitude #indiapharma #biopharma #cellandgenetherapy #innovationinhealthcare #startupindia Arun Anand, MD D A Prasanna Dr. Goutam Pujari Dr Manoj Kumar Singh Siddalingaswamy. C.A

Arun Anand, MD Board Director & COO Immuneel Therapeutics Pvt. Ltd. was invited to join an insightful panel discussion on the topic “Cell & Gene Therapy Development and Manufacture, Present & Future” at 4th Edition of the India Biopharma Leaders Conclave (IBLC), held at Le Meridien, Hyderabad, June 2024. Exploring the theme of “New Horizons in Biopharma, Biosimilars, & Biologics,” this session featured esteemed panelists who are pioneers in the field of cell and gene therapy and covered current landscape, challenges and innovations within the sector and future prospects of cell and gene therapy development and manufacturing. Dr. Arun Anand focused on highlighting the growing innovation in the field of cell & gene therapy, operational challenges and guidance on navigating regulatory landscapes and optimized manufacturing. He emphasized the importance of harmonizing regulatory requirements globally to expedite therapy development and innovation, especially for gene therapies. The India Biopharma Leaders Conclave showcases renowned speakers and eminent leaders from around the world coming together to exaggerate the present to imagine a future where biopharma holding the promise of transforming millions of lives. Immuneel has a pioneering journey in India from incorporation towards its first product approval for Varnimcabtagene autoleucel (CD19 CAR-T) within 4 years and looking forward to commercialization of var-cel reaching patients in need. Read more: https://lnkd.in/gJQn-zU9 To know more about us, visit: www.immuneel.com #immuneel #cellandgenetherapy #IBLC2024 #conference #paneldiscussion #leadership #immunotherapy #futureofmedicine #innovationinhealthcare #startupindia #bluetechmedia #mediacoverage #neosciencehub Arun Anand, MD Dr Akhilesh Sharma - MD, FRCP(Liverpool)CClin((USA),CPV (U.K) Murali Addepalli PhD  Dr. Ananda Gopu PERUMAL, (Ph.D) Renjitha Gopurappilly